Search

Your search keyword '"Pierce, Lori"' showing total 926 results
Start Over Author "Pierce, Lori"
926 results on '"Pierce, Lori"'

7. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline

Author

Shaitelman, Simona F., Anderson, Bethany M., Arthur, Douglas W., Bazan, Jose G., Bellon, Jennifer R., Bradfield, Lisa, Coles, Charlotte E., Gerber, Naamit K., Kathpal, Madeera, Kim, Leonard, Laronga, Christine, Meattini, Icro, Nichols, Elizabeth M., Pierce, Lori J., Poppe, Matthew M., Spears, Patricia A., Vinayak, Shaveta, Whelan, Timothy, and Lyons, Janice A.

Published
2024
Full Text
View/download PDF

9. Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials

Author

Taylor, Carolyn, Dodwell, David, McGale, Paul, Hills, Robert K, Berry, Richard, Bradley, Rosie, Braybrooke, Jeremy, Clarke, Mike, Gray, Richard, Holt, Francesca, Liu, Zulian, Pan, Hongchao, Peto, Richard, Straiton, Ewan, Coles, Charlotte, Duane, Fran, Hennequin, Christophe, Jones, Glenn, Kühn, Thorsten, Oliveros, Sileida, Overgaard, Jens, Pritchard, Kathy I, Suh, Chang-Ok, Beake, Graham, Boddington, Clare, Davies, Christina, Davies, Lucy, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Kerr, Amanda, Liu, Hui, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Nakahara, Mariko, Read, Simon, Taylor, Hannah, Ferguson, John, Scheurlen, Hans, Zurrida, Stefano, Galimberti, Viviana, Ingle, James, Valagussa, Pinuccia, Veronesi, Umberto, Anderson, Stewart, Tang, Gong, Fisher, Bernard, Fossa, Sophie, Valborg Reinertsen, Kristin, Host, Herman, Muss, Hyman, Holli, Kaija, Albain, Kathy, Arriagada, Rodrigo, Bartlett, John, Bergsten-Nordström, Elizabeth, Bliss, Judith, Brain, Etienne, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Del Mastro, Lucia, Di Leo, Angelo, Dignam, James, Dowsett, Mitch, Ejlertsen, Bent, Francis, Prue, García-Sáenz, José Angel, Gelber, Rich, Gnant, Michael, Goetz, Matthew, Goodwin, Pam, Halpin-Murphy, Pat, Hayes, Dan, Hill, Catherine, Jagsi, Reshma, Janni, Wolfgang, Loibl, Sibylle, Mamounas, Eleftherios, Martín, Miguel, McIntosh, Stuart, Mukai, Hirofumi, Nekljudova, Valentina, Norton, Larry, Ohashi, Yasuo, Piccart, Martine, Pierce, Lori, Raina, Vinod, Rea, Daniel, Regan, Meredith, Robertson, John, Rutgers, Emiel, Salgado, Roberto, Slamon, Dennis, Spanic, Tanja, Sparano, Joseph, Steger, Guenther, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Wilcken, Nicholas, Wolmark, Norman, Yu, Ke-Da, Cameron, David, Bergh, Jonas, Swain, Sandra, Whelan, Tim, and Poortmans, Philip

Published
2023
Full Text
View/download PDF

10. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Author

Braybrooke, Jeremy, Bradley, Rosie, Gray, Richard, Hills, Robert K, Pan, Hongchao, Peto, Richard, Dodwell, David, McGale, Paul, Taylor, Carolyn, Aihara, Tomohiko, Anderson, Stewart, Blum, Joanne, Cardoso, Fatima, Chen, Xiaosong, Crown, John P, Ejlertsen, Bent, Friedl, Thomas W P, Harbeck, Nadia, Janni, Wolfgang, Jensen, Maj-Britt, Mamounas, Eleftherios, Narui, Kazutaka, Nitz, Ulrike, Norton, Larry, O'Shaughnessy, Joyce, Piccart, Martine, Robert, Nicholas, Shao, Zhi-Ming, Slamon, Dennis, Sparano, Joseph, Watanabe, Toru, Yothers, Greg, Yu, Ke-Da, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Davies, Lucy, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Lui, Hui, Lui, Zulian, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Buzdar, Aman, Suman, Vera J, Hunt, Kelly K, Leonard, Robert C F, Mansi, Janine, Delbaldo, Catherine, Piedbois, Pascal, Quinaux, Emmanuel, Fesl, Christian, Gnant, Michael, Sölkner, Lidija, Steger, Guenther, Eikesdal, Hans Petter, Lønning, Per Eystein, Bee, Valerie, Fung, Helena, Mackey, John, Martin, Miguel, Press, Michael, De Azambuja, Evandro, Gelber, Richard, Regan, Meredith, Di Leo, Angelo, Van Dooren, Veerle, Nogaret, Jean Marie, Bartlett, John, Chen, Bingshu E, Gelmon, Karen, Goss, Paul E, Levine, Mark N, Parulekar, Wendy, Pritchard, Kathleen I, Shepherd, Lois, Berry, Donald, Cirrincione, Constance, Shulman, Lawrence N, Winer, Eric, Gelman, Rebecca S, Harris, Jay R, Henderson, Craig, Shapiro, Charles L, Christiansen, Peer, Ewertz, Marianne, Mouridsen, Henning T, Van Leeuwen, Elise, Linn, Sabine, Van Rossum, Annelot G J, Van Tinteren, Harm, Van Werkhoven, Erik, Goldstein, Lori, Gray, Robert, Eiermann, Wolfgang, Gianni, Luca, Valagussa, Pinuccia, Bogaerts, Jan, Bonnefoi, Herve, Poncet, Coralie, Huovinen, Riikka, Joensuu, Heikki, Bonneterre, Jacques, Fargeot, Pierre, Fumoleau, Pierre, Kerbrat, Pierre, Luporsi, Elisabeth, Namer, Moïse, Carrasco, Eva M, Segui, Miguel Angel, Meisner, Christoph, Loibl, Sibylle, Nekljudova, Valentina, Thomssen, Christoph, Von Minckwitz, Gunter, Kümmel, Sherko, Lopez, Massimo, Vici, Patrizia, Fountzilas, George, Koliou, Georgia, Mavroudis, Dimitrios, Saloustros, Emmanouil, Brain, Etienne, Delaloge, Suzette, Michiels, Stefan, Mathoulin-Pelissier, Simone, Bines, Jose, Sarmento, Roberta M B, Bonadonna, Gianni, Brambilla, Cristina, Rossi, Anna, Bliss, Judith, Coombes, Raoul Charles, Kilburn, Lucy, Marty, Michel, Amadori, Dino, Boccardo, Francesco, Nanni, Oriana, Rubagotti, Alessandra, Scarpi, Emanuela, Masuda, Norikazu, Toi, Masakazu, Ueno, Takayuki, Ishikawa, Takashi, Matsumoto, Koji, Takao, Shintaro, Sommer, Harald, Foroglou, Pericles, Giokas, George, Kondylis, D, Lissaios, Byron, Reinisch, Mattea, Lee, Keun Seok, Nam, Byung-Ho, Ro, Jung Sil, De Matteis, Andrea, Perrone, Francesco, Tang, Gong, Wolmark, Norman, Hozumi, Yasuo, Nomura, Yasuo, Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, De Mastro, Lucia, Venturini, Macro, Delozier, Thierry, Lemonnier, Jerome, Martin, Anne-Laure, Roché, Henri, Spielmann, Marc, Chen, Xiasong, Shen, Kunwei, Albain, Kathy, Barlow, William, Budd, George T, Gralow, Julie, Hayes, Dan, Bartlett-Lee, Peter, Ellis, Paul, Bianco, Angelo Raffaele, De Laurentiis, Michelino, De Placido, Sabino, Wildiers, Hans, Hsu, Limin, Eremin, Oleg, Walker, Leslie G, Ahlgren, Johan, Blomqvist, Carl, Holmberg, Lars, Lindman, Henrik, Asmar, Lina, Jones, Stephen E, Gluz, Oleg, Liedtke, Cornelia, Arriagada, Rodrigo, Bergsten-Nordström, Elizabeth, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Dignam, James, Dowsett, Mitch, Francis, Prudence A, Goetz, Matthew P, Goodwin, Pam, Halpin-Murphy, Pat, Hill, Catherine, Jagsi, Reshma, Mukai, Hirofumi, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Raina, Vinod, Rea, Daniel, Robertson, John, Rutgers, Emiel, Salgado, Roberto, Spanic, Tanja, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Cameron, David, Bergh, Jonas, and Swain, Sandra M

Published
2023
Full Text
View/download PDF

11. TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination

Author

Chandler, Benjamin C, Moubadder, Leah, Ritter, Cassandra L, Liu, Meilan, Cameron, Meleah, Wilder-Romans, Kari, Zhang, Amanda, Pesch, Andrea M, Michmerhuizen, Anna R, Hirsh, Nicole, Androsiglio, Marlie, Ward, Tanner, Olsen, Eric, Niknafs, Yashar S, Merajver, Sofia, Thomas, Dafydd G, Brown, Powel H, Lawrence, Theodore S, Nyati, Shyam, Pierce, Lori J, Chinnaiyan, Arul, and Speers, Corey

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biotechnology, Cancer, Genetics, Breast Cancer, Breast Neoplasms, Cell Cycle Proteins, DNA Damage, Databases, Nucleic Acid, Female, Gene Expression Regulation, Neoplastic, Homologous Recombination, Humans, Neoplasm Proteins, Protein Serine-Threonine Kinases, Protein-Tyrosine Kinases, Radiation Tolerance, Breast cancer, DNA repair, Oncology, Radiation therapy, Therapeutics, Medical and Health Sciences, Immunology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Increased rates of locoregional recurrence are observed in patients with basal-like breast cancer (BC) despite the use of radiation therapy (RT); therefore, approaches that result in radiosensitization of basal-like BC are critically needed. Using patients' tumor gene expression data from 4 independent data sets, we correlated gene expression with recurrence to find genes significantly correlated with early recurrence after RT. The highest-ranked gene, TTK, was most highly expressed in basal-like BC across multiple data sets. Inhibition of TTK by both genetic and pharmacologic methods enhanced radiosensitivity in multiple basal-like cell lines. Radiosensitivity was mediated, at least in part, through persistent DNA damage after treatment with TTK inhibition and RT. Inhibition of TTK impaired homologous recombination (HR) and repair efficiency, but not nonhomologous end-joining, and decreased the formation of Rad51 foci. Reintroduction of wild-type TTK rescued both radioresistance and HR repair efficiency after TTK knockdown; however, reintroduction of kinase-dead TTK did not. In vivo, TTK inhibition combined with RT led to a significant decrease in tumor growth in both heterotopic and orthotopic, including patient-derived xenograft, BC models. These data support the rationale for clinical development of TTK inhibition as a radiosensitizing strategy for patients with basal-like BC, and efforts toward this end are currently underway.

Published
2020

12. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial

Author

Vicini, Frank A, Cecchini, Reena S, White, Julia R, Arthur, Douglas W, Julian, Thomas B, Rabinovitch, Rachel A, Kuske, Robert R, Ganz, Patricia A, Parda, David S, Scheier, Michael F, Winter, Kathryn A, Paik, Soonmyung, Kuerer, Henry M, Vallow, Laura A, Pierce, Lori J, Mamounas, Eleftherios P, McCormick, Beryl, Costantino, Joseph P, Bear, Harry D, Germain, Isabelle, Gustafson, Gregory, Grossheim, Linda, Petersen, Ivy A, Hudes, Richard S, Curran, Walter J, Bryant, John L, and Wolmark, Norman

Subjects
Breast Cancer, Comparative Effectiveness Research, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Adult, Aged, Brachytherapy, Breast Neoplasms, Combined Modality Therapy, Female, Humans, Lymphatic Metastasis, Mammography, Mastectomy, Segmental, Middle Aged, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Radiotherapy Dosage, Survival Rate, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundWhole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation.MethodsWe did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to receive either whole-breast irradiation (whole-breast irradiation group) or APBI (APBI group). Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed, and APBI was delivered as 34 Gy of brachytherapy or 38·5 Gy of external bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period. Randomisation was stratified by disease stage, menopausal status, hormone-receptor status, and intention to receive chemotherapy. Patients, investigators, and statisticians could not be masked to treatment allocation. The primary outcome of invasive and non-invasive IBTR as a first recurrence was analysed in the intention-to-treat population, excluding those patients who were lost to follow-up, with an equivalency test on the basis of a 50% margin increase in the hazard ratio (90% CI for the observed HR between 0·667 and 1·5 for equivalence) and a Cox proportional hazard model. Survival was assessed by intention to treat, and sensitivity analyses were done in the per-protocol population. This trial is registered with ClinicalTrials.gov, NCT00103181.FindingsBetween March 21, 2005, and April 16, 2013, 4216 women were enrolled. 2109 were assigned to the whole-breast irradiation group and 2107 were assigned to the APBI group. 70 patients from the whole-breast irradiation group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patients respectively were available for survival analysis. Further, three and four patients respectively were lost to clinical follow-up (ie, survival status was assessed by phone but no physical examination was done), leaving 2036 patients in the whole-breast irradiation group and 2089 in the APBI group evaluable for the primary outcome. At a median follow-up of 10·2 years (IQR 7·5-11·5), 90 (4%) of 2089 women eligible for the primary outcome in the APBI group and 71 (3%) of 2036 women in the whole-breast irradiation group had an IBTR (HR 1·22, 90% CI 0·94-1·58). The 10-year cumulative incidence of IBTR was 4·6% (95% CI 3·7-5·7) in the APBI group versus 3·9% (3·1-5·0) in the whole-breast irradiation group. 44 (2%) of 2039 patients in the whole-breast irradiation group and 49 (2%) of 2093 patients in the APBI group died from recurring breast cancer. There were no treatment-related deaths. Second cancers and treatment-related toxicities were similar between the two groups. 2020 patients in the whole-breast irradiation group and 2089 in APBI group had available data on adverse events. The highest toxicity grade reported was: grade 1 in 845 (40%), grade 2 in 921 (44%), and grade 3 in 201 (10%) patients in the APBI group, compared with grade 1 in 626 (31%), grade 2 in 1193 (59%), and grade 3 in 143 (7%) in the whole-breast irradiation group.InterpretationAPBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy. Our trial had broad eligibility criteria, leading to a large, heterogeneous pool of patients and sufficient power to detect treatment equivalence, but was not designed to test equivalence in patient subgroups or outcomes from different APBI techniques. For patients with early-stage breast cancer, our findings support whole-breast irradiation following lumpectomy; however, with an absolute difference of less than 1% in the 10-year cumulative incidence of IBTR, APBI might be an acceptable alternative for some women.FundingNational Cancer Institute, US Department of Health and Human Services.

Published
2019

15. Evaluation of Dose Accuracy in the Near-Surface Region for Whole Breast Irradiation Techniques in a Multi-institutional Consortium

Author

Moncion, Alexander, Wilson, Melissa, Ma, Ruimei, Marsh, Robin, Burmeister, Jay, Dryden, Daniel, Lack, Danielle, Grubb, Margaret, Mayville, Alan, Jursinic, Paul, Dess, Kathryn, Kamp, Justin, Young, Kellen, Dilworth, Joshua T., Kestin, Larry, Jagsi, Reshma, Mietzel, Melissa, Vicini, Frank, Pierce, Lori J., and Moran, Jean M.

Published
2022
Full Text
View/download PDF

16. Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery.

Author

Ganz, Patricia A, Cecchini, Reena S, White, Julia R, Vicini, Frank A, Arthur, Douglas W, Rabinovitch, Rachel A, Kuske, Robert R, Julian, Thomas B, Parda, David S, Scheier, Michael F, Winter, Kathryn A, Paik, Soonmyung, Kuerer, Henry M, Vallow, Laura A, Pierce, Lori J, Mamounas, Eleftherios P, McCormick, Beryl, Bear, Harry D, Germain, Isabelle, and Gustafson, Gregory S

Subjects
END of treatment, BREAST cancer surgery, ACCELERATED partial breast irradiation, LUMPECTOMY, TREATMENT effectiveness, FATIGUE (Physiology)
Abstract

Background NRG Oncology NSABP B-39/RTOG 0413 compared whole-breast irradiation (WBI) to accelerated partial-breast irradiation (APBI). APBI was not equivalent to WBI in local tumor control. Secondary outcome was quality of life (QOL). Methods The QOL sub-study used validated self-report questionnaires, including the Breast Cancer Treatment Outcome Scale (BCTOS) and the 36-Item Short Form Health Survey (SF-36) vitality scale. Assessments occurred before random assignment, at treatment completion (chemotherapy or radiotherapy), 4 weeks later, at 6, 12, 24, and 36 months. Primary aims: cosmesis change equivalency (baseline to 3 years; a priori margin of equivalence 0.4 standard deviations) and fatigue change superiority (baseline to end of treatment [EOT]) for APBI vs WBI, by patient groups treated with or without chemotherapy when appropriate. Results From March 21, 2005 to May 25, 2009, 975 patients enrolled in this sub-study; 950 had follow-up data. APBI had 3-year cosmesis equivalent to WBI (95% CI = -0.0001 to -0.16; equivalence margin -0.22 to -0.22) in all patients. The APBI group without chemotherapy had less EOT fatigue (P  = .011; mean score APBI 63 vs WBI 59); the APBI group receiving chemotherapy had worse EOT fatigue (P  = .011; APBI 43 vs WBI 49). The APBI group reported less pain (BCTOS) at EOT (WBI 2.29 vs APBI 1.97) but worse pain at 3 years (WBI 1.62 vs APBI 1.71). APBI patients reported greater convenience of care than with WBI and reported less symptom severity at EOT and 4 weeks later. Conclusion Cosmetic outcomes were similar for the APBI and WBI groups, with small statistically significant differences in other outcomes that varied over time. Differences in fatigue and other symptoms appeared to resolve by ≥6 months. APBI may be preferred by some patients, for whom extended treatment is burdensome. ClinicalTrials.gov NCT00103181. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

17. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

Author

Bradley, Rosie, Braybrooke, Jeremy, Gray, Richard, Hills, Robert K, Liu, Zulian, Pan, Hongchao, Peto, Richard, Dodwell, David, McGale, Paul, Taylor, Carolyn, Francis, Prudence A, Gnant, Michael, Perrone, Francesco, Regan, Meredith M, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Davies, Lucy, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Liu, Hui, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Jakesz, Raimund, Fesl, Christian, Pagani, Olivia, Gelber, Richard, De Laurentiis, Michelino, De Placido, Sabino, Gallo, Ciro, Albain, Kathy, Anderson, Stewart, Arriagada, Rodrigo, Bartlett, John, Bergsten-Nordström, Elizabeth, Bliss, Judith, Brain, Etienne, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Del Mastro, Lucia, Di Leo, Angelo, Dignam, James, Dowsett, Mitch, Ejlertsen, Bent, Goetz, Matthew, Goodwin, Pam, Halpin-Murphy, Pat, Hayes, Dan, Hill, Catherine, Jagsi, Reshma, Janni, Wolfgang, Loibl, Sibylle, Mamounas, Eleftherios P, Martín, Miguel, Mukai, Hirofumi, Nekljudova, Valentina, Norton, Larry, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Pritchard, Kathleen I, Raina, Vinod, Rea, Daniel, Robertson, John, Rutgers, Emiel, Spanic, Tanja, Sparano, Joseph, Steger, Guenther, Tang, Gong, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Wolmark, Norman, Cameron, David, Bergh, Jonas, and Swain, Sandra M

Published
2022
Full Text
View/download PDF

21. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

Author

Bradley, Rosie, Braybrooke, Jeremy, Gray, Richard, Hills, Robert, Liu, Zulian, Peto, Richard, Davies, Lucy, Dodwell, David, McGale, Paul, Pan, Hongchao, Taylor, Carolyn, Anderson, Stewart, Gelber, Richard, Gianni, Luca, Jacot, William, Joensuu, Heikki, Moreno-Aspitia, Alvaro, Piccart, Martine, Press, Michael, Romond, Edward, Slamon, Dennis, Suman, Vera, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Liu, Hui, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Wang, Yaochen, Crown, John, de Azambuja, Evandro, Delaloge, Suzette, Fung, Helena, Geyer, Charles, Spielmann, Marc, Valagussa, Pinuccia, Albain, Kathy, Arriagada, Rodrigo, Bartlett, John, Bergsten-Nordström, Elizabeth, Bliss, Judith, Brain, Etienne, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Del Mastro, Lucia, Di Leo, Angelo, Dignam, James, Dowsett, Mitch, Ejlertsen, Bent, Francis, Prue, Gnant, Michael, Goetz, Matthew, Goodwin, Pam, Halpin-Murphy, Pat, Hayes, Dan, Hill, Catherine, Jagsi, Reshma, Janni, Wolfgang, Loibl, Sibylle, Mamounas, Eleftherios P, Martín, Miguel, Mukai, Hirofumi, Nekljudova, Valentina, Norton, Larry, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Raina, Vinod, Rea, Daniel, Regan, Meredith, Robertson, John, Rutgers, Emiel, Spanic, Tanja, Sparano, Joseph, Steger, Guenther, Tang, Gong, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Wolmark, Norman, Cameron, David, Bergh, Jonas, Pritchard, Kathleen I, and Swain, Sandra M

Published
2021
Full Text
View/download PDF

24. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer

Author

Speers, Corey, Zhao, Shuang G, Chandler, Ben, Liu, Meilan, Wilder-Romans, Kari, Olsen, Eric, Nyati, Shyam, Ritter, Cassandra, Alluri, Prasanna G, Kothari, Vishal, Hayes, Daniel F, Lawrence, Theodore S, Spratt, Daniel E, Wahl, Daniel R, Pierce, Lori J, and Feng, Felix Y

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Biotechnology, Genetics, Breast Cancer, Clinical sciences, Oncology and carcinogenesis, Epidemiology
Abstract

Increased rates of locoregional recurrence have been observed in triple-negative breast cancer despite chemotherapy and radiation therapy. Thus, approaches that combine therapies for radiosensitization in triple-negative breast cancer are critically needed. We characterized the radiation therapy response of 21 breast cancer cell lines and paired this radiation response data with high-throughput drug screen data to identify androgen receptor as a top target for radiosensitization. Our radiosensitizer screen nominated bicalutamide as the drug most effective in treating radiation therapy-resistant breast cancer cell lines. We subsequently evaluated the expression of androgen receptor in >2100 human breast tumor samples and 51 breast cancer cell lines and found significant heterogeneity in androgen receptor expression with enrichment at the protein and RNA level in triple-negative breast cancer. There was a strong correlation between androgen receptor RNA and protein expression across all breast cancer subtypes (R2 = 0.72, p

Published
2017

26. Supplementary Figure S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial

Author

Stenmark Tullberg, Axel, primary, Sjöström, Martin, primary, Niméus, Emma, primary, Killander, Fredrika, primary, Chang, S. Laura, primary, Feng, Felix Y., primary, Speers, Corey W., primary, Pierce, Lori J., primary, Kovács, Anikó, primary, Lundstedt, Dan, primary, Holmberg, Erik, primary, and Karlsson, Per, primary

Published
2024
Full Text
View/download PDF

27. Supplementary Tables S5-S11 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial

Author

Stenmark Tullberg, Axel, primary, Sjöström, Martin, primary, Niméus, Emma, primary, Killander, Fredrika, primary, Chang, S. Laura, primary, Feng, Felix Y., primary, Speers, Corey W., primary, Pierce, Lori J., primary, Kovács, Anikó, primary, Lundstedt, Dan, primary, Holmberg, Erik, primary, and Karlsson, Per, primary

Published
2024
Full Text
View/download PDF

28. Study protocol S1 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial

Author

Stenmark Tullberg, Axel, primary, Sjöström, Martin, primary, Niméus, Emma, primary, Killander, Fredrika, primary, Chang, S. Laura, primary, Feng, Felix Y., primary, Speers, Corey W., primary, Pierce, Lori J., primary, Kovács, Anikó, primary, Lundstedt, Dan, primary, Holmberg, Erik, primary, and Karlsson, Per, primary

Published
2024
Full Text
View/download PDF

29. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer

Author

Speers, Corey, Zhao, Shuang G, Kothari, Vishal, Santola, Alyssa, Liu, Meilan, Wilder-Romans, Kari, Evans, Joseph, Batra, Nidhi, Bartelink, Harry, Hayes, Daniel F, Lawrence, Theodore S, Brown, Powel H, Pierce, Lori J, and Feng, Felix Y

Subjects
Cancer, Breast Cancer, Animals, Biomarkers, Tumor, Cell Line, Tumor, Cell Proliferation, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, MCF-7 Cells, Mice, Neoplasm Recurrence, Local, Protein Serine-Threonine Kinases, Radiation Tolerance, Receptor, ErbB-2, Triple Negative Breast Neoplasms, Receptor, erbB-2, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeWhile effective targeted therapies exist for estrogen receptor-positive and HER2-positive breast cancer, no such effective therapies exist for triple-negative breast cancer (TNBC); thus, it is clear that additional targets for radiosensitization and treatment are critically needed.Experimental designExpression microarrays, qRT-PCR, and Western blotting were used to assess MELK RNA and protein expression levels. Clonogenic survival assays were used to quantitate the radiosensitivity of cell lines at baseline and after MELK inhibition. The effect of MELK knockdown on DNA damage repair kinetics was determined using γH2AX staining. The in vivo effect of MELK knockdown on radiosensitivity was performed using mouse xenograft models. Kaplan-Meier analysis was used to estimate local control and survival information, and a Cox proportional hazards model was constructed to identify potential factors impacting local recurrence-free survival.ResultsMELK expression is significantly elevated in breast cancer tissues compared with normal tissue as well as in TNBC compared with non-TNBC. MELK RNA and protein expression is significantly correlated with radioresistance in breast cancer cell lines. Inhibition of MELK (genetically and pharmacologically) induces radiation sensitivity in vitro and significantly delayed tumor growth in vivo in multiple models. Kaplan-Meier survival and multivariable analyses identify increasing MELK expression as being the strongest predictor of radioresistance and increased local recurrence in multiple independent datasets.ConclusionsHere, we identify MELK as a potential biomarker of radioresistance and target for radiosensitization in TNBC. Our results support the rationale for developing clinical strategies to inhibit MELK as a novel target in TNBC. Clin Cancer Res; 22(23); 5864-75. ©2016 AACR.

Published
2016

30. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.

Author

Niknafs, Yashar S, Han, Sumin, Ma, Teng, Speers, Corey, Zhang, Chao, Wilder-Romans, Kari, Iyer, Matthew K, Pitchiaya, Sethuramasundaram, Malik, Rohit, Hosono, Yasuyuki, Prensner, John R, Poliakov, Anton, Singhal, Udit, Xiao, Lanbo, Kregel, Steven, Siebenaler, Ronald F, Zhao, Shuang G, Uhl, Michael, Gawronski, Alexander, Hayes, Daniel F, Pierce, Lori J, Cao, Xuhong, Collins, Colin, Backofen, Rolf, Sahinalp, Cenk S, Rae, James M, Chinnaiyan, Arul M, and Feng, Felix Y

Subjects
Cell Line, Tumor, Humans, Breast Neoplasms, Neoplasm Invasiveness, Tamoxifen, Receptors, Estrogen, Antineoplastic Agents, Hormonal, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Female, Gene Knockdown Techniques, RNA, Long Noncoding, Antineoplastic Agents, Hormonal, Cell Line, Tumor, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, RNA, Long Noncoding, Receptors, Estrogen
Abstract

Molecular classification of cancers into subtypes has resulted in an advance in our understanding of tumour biology and treatment response across multiple tumour types. However, to date, cancer profiling has largely focused on protein-coding genes, which comprise

Published
2016

35. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Author

Gray, Richard, Bradley, Rosie, Braybrooke, Jeremy, Liu, Zulian, Peto, Richard, Davies, Lucy, Dodwell, David, McGale, Paul, Pan, Hongchao, Taylor, Carolyn, Barlow, William, Bliss, Judith, Bruzzi, Paolo, Cameron, David, Fountzilas, George, Loibl, Sibylle, Mackey, John, Martin, Miguel, Del Mastro, Lucia, Möbus, Volker, Nekljudova, Valentina, De Placido, Sabino, Swain, Sandra, Untch, Michael, Pritchard, Kathleen I, Bergh, Jonas, Norton, Larry, Boddington, Clare, Burrett, Julie, Clarke, Mike, Davies, Christina, Duane, Fran, Evans, Vaughan, Gettins, Lucy, Godwin, Jon, Hills, Robert, James, Sam, Liu, Hui, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Wang, Yaochen, Wang, Zhe, Fasching, Peter, Harbeck, Nadia, Piedbois, Pascal, Gnant, Michael, Steger, Guenther, Di Leo, Angelo, Dolci, Stella, Francis, Prue, Larsimont, Denis, Nogaret, Jean Marie, Philippson, Catherine, Piccart, Martine, Linn, Sabine, Peer, Petronella, Tjan-Heijnen, Vivianne, Vliek, Sonja, Slamon, Dennis, Bartlett, John, Bramwell, Vivien H, Chen, Bingshu, Chia, Stephen, Gelmon, Karen, Goss, Paul, Levine, Mark, Parulekar, Wendy, Pater, Joseph, Rakovitch, Eileen, Shepherd, Lois, Tu, Dongsheng, Whelan, Tim, Berry, Don, Broadwater, Gloria, Cirrincione, Constance, Muss, Hyman, Weiss, Raymond, Shan, Yi, Shao, Yong Fu, Wang, Xiang, Xu, Binghe, Zhao, Dong-Bing, Bartelink, Harry, Bijker, Nina, Bogaerts, Jan, Cardoso, Fatima, Cufer, Tanja, Julien, Jean-Pierre, Poortmans, Philip, Rutgers, Emiel, van de Velde, Cornelis, Carrasco, Eva, Segui, Miguel Angel, Blohmer, Jens Uwe, Costa, Serban, Gerber, Bernd, Jackisch, Christian, von Minckwitz, Gunter, Giuliano, Mario, De Laurentiis, Michele, Bamia, Christina, Koliou, Georgia-Angeliki, Mavroudis, Dimitris, A'Hern, Roger, Ellis, Paul, Kilburn, Lucy, Morden, James, Yarnold, John, Sadoon, Mohammad, Tulusan, Augustinus H, Anderson, Stewart, Bass, Gordon, Costantino, Joe, Dignam, James, Fisher, Bernard, Geyer, Charles, Mamounas, Eleftherios P, Paik, Soon, Redmond, Carol, Wickerham, D Lawrence, Venturini, Marco, Bighin, Claudia, Pastorino, Simona, Pronzato, Paolo, Sertoli, Mario Roberto, Foukakis, Theodorus, Albain, Kathy, Arriagada, Rodrigo, Bergsten Nordström, Elizabeth, Boccardo, Francesco, Brain, Etienne, Carey, Lisa, Coates, Alan, Coleman, Robert, Correa, Candace, Cuzick, Jack, Davidson, Nancy, Dowsett, Mitch, Ewertz, Marianne, Forbes, John, Gelber, Richard, Goldhirsch, Aron, Goodwin, Pamela, Hayes, Daniel, Hill, Catherine, Ingle, James, Jagsi, Reshma, Janni, Wolfgang, Mukai, Hirofumi, Ohashi, Yasuo, Pierce, Lori, Raina, Vinod, Ravdin, Peter, Rea, Daniel, Regan, Meredith, Robertson, John, Sparano, Joseph, Tutt, Andrew, Viale, Giuseppe, Wilcken, Nicholas, Wolmark, Norman, Wood, Wiliam, and Zambetti, Milvia

Published
2019
Full Text
View/download PDF

37. Validation of Prognostic Value of Profile for Omission of Adjuvant Radiotherapy (Polar) in the Scottish Conservation Trial in Early Breast Cancer

Author

Taylor, Karen J., primary, Bartlett, John M.S., additional, Bennett, John P., additional, Chang, S. Laura, additional, Arrick, Bradley, additional, Baehner, Frederick L., additional, Loane, Joseph F., additional, Piper, Tammy, additional, Mallon, Elizabeth A., additional, Dunlop, Joanna, additional, Jack, Wilma, additional, Caldwell, Jacqueline, additional, Kunkler, Ian, additional, Williams, Linda J., additional, Speers, Corey W., additional, Feng, Felix, additional, Pierce, Lori J., additional, and Cameron, David, additional

Published
2024
Full Text
View/download PDF

39. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Author

Asselain, Bernard, Barlow, William, Bartlett, John, Bergh, Jonas, Bergsten-Nordström, Elizabeth, Bliss, Judith, Boccardo, Francesco, Boddington, Clare, Bogaerts, Jan, Bonadonna, Gianni, Bradley, Rosie, Brain, Etienne, Braybrooke, Jeremy, Broet, Philippe, Bryant, John, Burrett, Julie, Cameron, David, Clarke, Mike, Coates, Alan, Coleman, Robert, Coombes, Raoul Charles, Correa, Candace, Costantino, Joe, Cuzick, Jack, Danforth, David, Davidson, Nancy, Davies, Christina, Davies, Lucy, Di Leo, Angelo, Dodwell, David, Dowsett, Mitch, Duane, Fran, Evans, Vaughan, Ewertz, Marianne, Fisher, Bernard, Forbes, John, Ford, Leslie, Gazet, Jean-Claude, Gelber, Richard, Gettins, Lucy, Gianni, Luca, Gnant, Michael, Godwin, Jon, Goldhirsch, Aron, Goodwin, Pamela, Gray, Richard, Hayes, Daniel, Hill, Catherine, Ingle, James, Jagsi, Reshma, Jakesz, Raimund, James, Sam, Janni, Wolfgang, Liu, Hui, Liu, Zulian, Lohrisch, Caroline, Loibl, Sibylle, MacKinnon, Liz, Makris, Andreas, Mamounas, Eleftherios, Mannu, Gurdeep, Martín, Miguel, Mathoulin, Simone, Mauriac, Louis, McGale, Paul, McHugh, Theresa, Morris, Philip, Mukai, Hirofumi, Norton, Larry, Ohashi, Yasuo, Olivotto, Ivo, Paik, Soon, Pan, Hongchao, Peto, Richard, Piccart, Martine, Pierce, Lori, Poortmans, Philip, Powles, Trevor, Pritchard, Kathy, Ragaz, Joseph, Raina, Vinod, Ravdin, Peter, Read, Simon, Regan, Meredith, Robertson, John, Rutgers, Emiel, Scholl, Suzy, Slamon, Dennis, Sölkner, Lidija, Sparano, Joseph, Steinberg, Seth, Sutcliffe, Rosemary, Swain, Sandra, Taylor, Carolyn, Tutt, Andrew, Valagussa, Pinuccia, van de Velde, Cornelis, van der Hage, Jos, Viale, Giuseppe, von Minckwitz, Gunter, Wang, Yaochen, Wang, Zhe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Winer, Eric, Wolmark, Norman, Wood, William, Zambetti, Milvia, and Zujewski, Jo Anne

Published
2018
Full Text
View/download PDF

44. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline

Author

Shaitelman, Simona F., primary, Anderson, Bethany M., additional, Arthur, Douglas W., additional, Bazan, Jose G., additional, Bellon, Jennifer R., additional, Bradfield, Lisa, additional, Coles, Charlotte E., additional, Gerber, Naamit K., additional, Kathpal, Madeera, additional, Kim, Leonard, additional, Laronga, Christine, additional, Meattini, Icro, additional, Nichols, Elizabeth M., additional, Pierce, Lori J., additional, Poppe, Matthew M., additional, Spears, Patricia A., additional, Vinayak, Shaveta, additional, Whelan, Timothy, additional, and Lyons, Janice A., additional

Published
2023
Full Text
View/download PDF

45. Factors Associated With Cardiac Radiation Dose Reduction After Hypofractionated Radiation Therapy for Localized, Left-Sided Breast Cancer in a Large Statewide Quality Consortium

Author

Herr, Daniel J., primary, Moncion, Alexander, additional, Griffith, Kent A., additional, Marsh, Robin, additional, Grubb, Margaret, additional, Bhatt, Amit, additional, Dominello, Michael, additional, Walker, Eleanor M., additional, Narayana, Vrinda, additional, Abu-Isa, Eyad, additional, Vicini, Frank A., additional, Hayman, James A., additional, and Pierce, Lori J., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results